Latest:
Personalizing Treatment for HPV-Related Head and Neck Cancer
Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andrew Hendifar, MD, MPH
Latest:
Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer
Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).
Andrew J. Armstrong, MD
Latest:
Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC
Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.
Andrew J. Roth
Latest:
Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment
William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
Andrew Jennis, MD
Latest:
Dr. Jennis on Progress in Implementing Oncology Care Model
Andrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.
Andrew Kennedy, MD
Latest:
Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRC
Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).
Andrew L. Pecora, MD, FACP, CPE
Latest:
Dr. Pecora on JTCC Joining Georgetown Lombardi Cancer Consortium
Andrew L. Pecora, MD, FACP, CPE, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses John Theurer Cancer Center (JTCC) joining Georgetown Lombardi Cancer Consortium.